- Trial phase
- Approved
- Time to market
- Already on market since 2016
- Why 4/10
- Photrexa is an already-approved, marketed drug (since 2016) with no pending regulatory decision or hard binary catalyst in the next ~12 months. Its commercial trajectory is being superseded by Glaukos's next-gen Epioxa (approved Oct 2025). Per the impact score rubric, an approved drug with no pending regulatory decision scores 3-5; Photrexa lands at 4 because it remains a revenue contributor but is not the company's primary growth catalyst.
Photrexa itself has no upcoming binary catalyst, it is an approved, marketed legacy product. Investors should instead focus on Glaukos's next-generation Epioxa (epi-on CXL, approved Oct 2025) and iDose TR glaucoma platform as the primary growth drivers. Monitor quarterly earnings for Epioxa adoption trends and the company's $690M 2026 revenue guidance execution.
Price Chart
Executive Summary
Photrexa (riboflavin 5'-phosphate ophthalmic solution) is Glaukos Corporation's first-generation corneal collagen cross-linking (CXL) therapy, FDA-approved in 2016 as an orphan drug for progressive keratoconus and corneal ectasia. It is used with the KXL System in an "epithelium-off" procedure that requires removing the corneal surface layer. While Photrexa remains the only FDA-approved CXL therapy for keratoconus, its commercial importance is being eclipsed by Glaukos's next-generation product Epioxa (FDA-approved October 2025), a less-invasive "epithelium-on" version that does not require epithelium removal. For an investor, Photrexa is a mature, approved product with no pending binary catalyst, while the stock's key growth driver is the commercial ramp of Epioxa and the iDose TR glaucoma platform.
How It Works
Photrexa is a riboflavin (vitamin B2) solution used in a procedure called corneal collagen cross-linking (CXL). The riboflavin is applied to the eye and then activated by a specific UV light device (the KXL System). This activates the riboflavin to strengthen the collagen fibers in the cornea, the clear front part of the eye, halting the progression of keratoconus, a disease where the cornea progressively thins and bulges into a cone shape, causing vision loss. The original Photrexa procedure requires removing the thin outer layer of the cornea (epithelium) before treatment, which is why it's called "epi-off."
Trial Status
Photrexa was FDA-approved on April 15, 2016 (NDA 203324) as an orphan drug for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. It has been commercially marketed since 2016 and is the first-and-only FDA-approved corneal cross-linking therapy. The product is mature and established in the ophthalmic market.
The Two-Sided Case
Upcoming Catalysts
- No upcoming binary catalyst for Photrexa specifically, it is a mature approved product
- Glaukos quarterly earnings reports for overall company performance and Epioxa/iDose TR adoption
- Epioxa commercial ramp (approved Oct 2025, commercially available March 2026) is the relevant catalyst for GKOS stock
Source Filing
The SecBot filing or press-release report that triggered this drug report:
GLAUKOS Corp 8-K GKOS ·Originating report